Methodological variations affect the release of VEGF in vitro and fibrinolysis' time from platelet concentrates

PLoS One. 2020 Oct 7;15(10):e0240134. doi: 10.1371/journal.pone.0240134. eCollection 2020.

Abstract

Blood Concentrates (BCs) are autologous non-transfusional therapeutical preparations with biological properties applied in tissue regeneration. These BCs differ in the preparation method, in fibrin network architecture, growth factors release as well as in platelet/cell content. Methodological changes result in distinct matrices that can compromise their clinical effectiveness. The present study evaluated the influence of different g-forces and types of tubes in the release of vascular endothelial growth factor (VEGF) from platelet-rich fibrin (PRF) as a function of time. The PRF-like samples were obtained with three g-forces (200, 400, and 800 x g) for 10 minutes in pure glass tubes or in polystyrene-clot activator tubes. Scanning and Transmission electron microscopy was used to morphometric analyzes of PRF's specimens and flow cytometry was used to quantify VEGF slow release until 7 days. Our results showed that platelets were intact and adhered to the fibrin network, emitting pseudopods and in degranulation. The fibrin network was rough and twisted with exosomic granulations impregnated on its surface. An increase in the concentration of VEGF in the PRF supernatant was observed until 7 days for all g forces (200, 400 or 800 xg), with the highest concentrations observed with 200 x g, in both tubes, glass or plastic. Morphological analyzes showed a reduction in the diameter of the PRF fibers after 7 days. Our results showed that g-force interferes with the shape of the fibrin network in the PRF, as well as affect the release of VEGF stored into platelets. This finding may be useful in applying PRF to skin lesions, in which the rapid release of growth factors can favor the tissue repair process. Our observations point to a greater clarification on the methodological variations related to obtaining PRF matrices, as they can generate products with different characteristics and degrees of effectiveness in specific applications.

MeSH terms

  • Blood Platelets / metabolism*
  • Blood Platelets / ultrastructure
  • Centrifugation / adverse effects
  • Centrifugation / methods
  • Female
  • Fibrin / metabolism
  • Fibrin / ultrastructure
  • Fibrinolysis*
  • Healthy Volunteers
  • Humans
  • Microscopy, Electron, Scanning
  • Microscopy, Electron, Transmission
  • Platelet-Rich Fibrin / metabolism*
  • Tissue Engineering / methods*
  • Vascular Endothelial Growth Factor A / analysis
  • Vascular Endothelial Growth Factor A / metabolism*

Substances

  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Fibrin

Grants and funding

The author(s) received no specific funding for this work.